La prevención de las úlceras pépticas con esomeprazol en pacientes con riesgo de desarrollar úlceras tratadas con ácido acetilsalicílico en dosis bajas: un ensayo controlado aleatorio (OBERÓN).

OBJECTIVE:

To determine whether once-daily esomeprazole 40 mg or 20 mg compared with placebo reduces the incidence of peptic ulcers over 26 weeks of treatment in patients taking low-dose acetylsalicylic acid (ASA) and who are at risk for ulcer development.

DESIGN:

Multinational, randomised, blinded, parallel-group, placebo-controlled trial.

SETTING:

Cardiology, primary care and gastroenterology centres (n=240).

PATIENTS:

Helicobacter pylori-negative patients taking daily low-dose ASA (75-325 mg), who fulfilled one or more of the following criteria: age ≥18 years with history of uncomplicated peptic ulcer; age ≥60 years with either stable coronary artery disease, upper gastrointestinal symptoms and five or more gastric/duodenal erosions, or low-dose ASA treatment initiated within 1 month of randomisation; or age ≥65 years. All patients were ulcer-free at study entry.

INTERVENTIONS:

Once-daily, blinded treatment with esomeprazole 40 mg, 20 mg or placebo for 26 weeks.

MAIN OUTCOME MEASURES:

The primary end point was the occurrence of endoscopy-confirmed peptic ulcer over 26 weeks.

RESULTS:

A total of 2426 patients (52% men; mean age 68 years) were randomised. After 26 weeks, esomeprazole 40 mg and 20 mg significantly reduced the cumulative proportion of patients developing peptic ulcers; 1.5% of esomeprazole 40 mg and 1.1% of esomeprazole 20 mg recipients, compared with 7.4% of placebo recipients, developed peptic ulcers (both p<0.0001 vs placebo). Esomeprazole was generally well tolerated. Conclusions Acid-suppressive treatment with once-daily esomeprazole 40 mg or 20 mg reduces the occurrence of peptic ulcers in patients at risk for ulcer development who are taking low-dose ASA. Clinical trial registration number ClinicalTrials.gov identifier: NCT00441727.